Literature DB >> 3435068

Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.

M M Mouradian1, J L Juncos, G Fabbrini, T N Chase.   

Abstract

The response to continuous intravenous infusion of levodopa was evaluated in 23 patients with Parkinson's disease complicated by motor fluctuations. Conversion from oral to intravenous levodopa treatment resulted in an immediate and sustained stabilization of plasma levodopa levels in both the wearing-off and on-off groups. Motor variability also diminished within the first 24 hours of infusion, although to a much greater extent in patients with the wearing-off phenomenon. Over the next 5 to 11 days of intravenous treatment, further reductions in motor fluctuations occurred in both groups, at a substantially faster rate in the wearing-off group than in the on-off group. The degree of immediate stabilization of parkinsonian motor response correlated best with disease duration, whereas the rate of subsequent improvement correlated most closely with levodopa dose. The results support the view that the wearing-off phenomenon may reflect the degeneration of dopamine terminals as a consequence of natural disease progression with a resultant inability to buffer variations in levodopa availability; the on-off phenomenon may reflect additional postsynaptic changes, possibly occurring in response to the nonphysiological fluctuations in synaptic dopamine, which gradually remit during continuous levodopa administration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3435068     DOI: 10.1002/ana.410220406

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  31 in total

1.  Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist.

Authors:  K Tanaka; I Miyazaki; N Fujita; M E Haque; M Asanuma; N Ogawa
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

2.  Pharmacokinetics and effects of levodopa in advanced Parkinson's disease.

Authors:  E Bredberg; J Tedroff; S M Aquilonius; L Paalzow
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Relations between on-off phenomena and cognitive functions in Parkinson disease.

Authors:  G Meco; V Bonifati; L Bedini; A Bellatreccia; N Vanacore; A Franzese
Journal:  Ital J Neurol Sci       Date:  1991-02

Review 4.  Soluble and controlled-release preparations of levodopa: do we really need them?

Authors:  Giovanni Fabbrini; Flavio Di Stasio; Maria Bloise; Alfredo Berardelli
Journal:  J Neurol       Date:  2010-11       Impact factor: 4.849

5.  A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance.

Authors:  J M Cedarbaum; M Hoey; F H McDowell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

6.  Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.

Authors:  M Yamamoto; M Yokochi; S Kuno; Y Hattori; Y Tsukamoto; H Narabayashi; H Tohgi; Y Mizuno; H Kowa; N Yanagisawa; I Kanazawa
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

7.  Diurnal differences in response to oral levodopa.

Authors:  J P Frankel; Z Pirtosek; P A Kempster; M Bovingdon; R Webster; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-11       Impact factor: 10.154

Review 8.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 9.  Localized delivery of proteins in the brain: can transport be customized?

Authors:  M F Haller; W M Saltzman
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

10.  Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease.

Authors:  S A Factor; J R Sanchez-Ramos; W J Weiner; A M Ingenito
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.